GlassScriptPhysician profile
Matthew T Moyer
NPI 1417174749
$4,510.25
in general payments reported to CMS, 2019-2025
11 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2021: $2,977 · 2022: $104 · 2023: $386 · 2024: $317 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.94 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,952.77 | 2019-2025 | Resolution 360 Clip |
| Janssen Biotech, INC. | $692.11 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $263.60 | 2019-2024 | |
| Braintree Laboratories, INC. | $191.94 | 2021-2025 | Sutab, Suflave |
| Cook Medical LLC | $167.65 | 2022-2023 | Fusion, Hemospray |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.04 | 2023-2024 | Plenvu, Xifaxan |
| Fujifilm Healthcare Americas Corporation | $72.43 | 2021 | |
| Ferring Pharmaceuticals INC. | $32.70 | 2022-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $21.53 | 2025 | Iqirvo |
| Pfizer INC. | $18.61 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.87 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Moyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.